In recent years, the Incretin-Based Therapies (IBTs) of T2DM (through Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA), DiPeptidyl Peptidase-4 inhibitors (DPP-4is), and Sodium/GLucose coTransporter 2 inhibitors (SGLT2is)) have been simplified and widely used. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.